RxDoctor Payments Data

Kevin Tally, MD

Cardiovascular Disease · Hartford, CTNPI 1285624809

Payments from drug & device makers

$918in general payments, 2019–2025

Across 28 payments — averaging $32.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$163
  • Abbott$161
  • AstraZeneca$154
  • Pfizer$121
  • Amgen$93
  • Boston Scientific$50
  • plus $177 from 6 others

What the payments were for

  • Food & beverage$70377%
  • Education$21523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$918 in reported general payments places this provider in the 40th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$237,039
Medicare patients
1,606
Services billed
3,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban674$897,779
VyndamaxTafamidis15$881,524
XareltoRivaroxaban314$392,759
EntrestoSacubitril/Valsartan154$220,959
FarxigaDapagliflozin Propanediol100$119,184
JardianceEmpagliflozin58$100,262
Repatha SureclickEvolocumab74$84,951
MultaqDronedarone Hcl23$43,345
Praluent PenAlirocumab21$18,274
VascepaIcosapent Ethyl24$14,143
VeltassaPatiromer Calcium Sorbitex12$13,778
Metoprolol Succinate910$13,314
Ezetimibe313$9,519
Carvedilol ErCarvedilol Phosphate20$6,397
Atorvastatin Calcium668$6,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$121$1,779,303689 claims
Johnson & JohnsonXarelto$18$392,759314 claims
NovartisEntresto$29$220,959154 claims
AstraZenecaFarxiga$154$119,184100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →